Literature DB >> 28508663

18F-FDG PET/CT in polymyalgia rheumatica-a pictorial review.

Zdenek Rehak1,2,3, Andrea Sprlakova-Pukova4, Tomas Kazda5, Zdenek Fojtik6, Lenka Vargova7, Petr Nemec8.   

Abstract

Polymyalgia rheumatica (PMR) is one of the inflammatory rheumatic diseases that can potentially be detected by positron emission tomography/CT. High fluorine-18 fludeoxyglucose (18F-FDG) accumulation around the shoulders, sternoclavicular and hip joints are the most common pre-treatment features of patients with PMR. Another common sign is increased 18F-FDG uptake in extra-articular regions between columnal spinous processes, near ischial tuberosities and in the praepubic area. Some patients also present with high 18F-FDG uptake in main arteries, corresponding to the characteristics of giant cell arteritis. It is possible to observe a decrease or even a disappearance of 18F-FDG uptake after effective therapy, an event which may be useful for the monitoring of treatment as well as for detection of PMR relapse.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28508663      PMCID： PMC5603955          DOI： 10.1259/bjr.20170198

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  12 in total

1.  Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients.

Authors:  D Blockmans; L De Ceuninck; S Vanderschueren; D Knockaert; L Mortelmans; H Bobbaers
Journal:  Rheumatology (Oxford)       Date:  2006-11-18       Impact factor: 7.580

2.  Various forms of (18)F-FDG PET and PET/CT findings in patients with polymyalgia rheumatica.

Authors:  Zdenek Rehak; Jiri Vasina; Petr Nemec; Zdenek Fojtik; Renata Koukalova; Zbynek Bortlicek; Dorota Rehakova; Jan Adam; Alena Vavrusova; Zdenek Adam
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2015-05-25       Impact factor: 1.245

3.  Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study.

Authors:  Maxime Sondag; Xavier Guillot; Frank Verhoeven; Oleg Blagosklonov; Clément Prati; Hatem Boulahdour; Daniel Wendling
Journal:  Rheumatology (Oxford)       Date:  2016-04-23       Impact factor: 7.580

4.  Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.

Authors:  X Palard-Novello; S Querellou; M Gouillou; A Saraux; T Marhadour; F Garrigues; R Abgral; P Y Salaün; V Devauchelle-Pensec
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-11       Impact factor: 9.236

Review 5.  Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis.

Authors:  Dario Camellino; Marco A Cimmino
Journal:  Rheumatology (Oxford)       Date:  2011-05-12       Impact factor: 7.580

6.  Differences in fluorodeoxyglucose positron emission tomography/computed tomography findings between elderly onset rheumatoid arthritis and polymyalgia rheumatica.

Authors:  Hiroyuki Takahashi; Hiroyuki Yamashita; Kazuo Kubota; Yoko Miyata; Momoko Okasaki; Miyako Morooka; Yuko Takahashi; Hiroshi Kaneko; Toshikazu Kano; Akio Mimori
Journal:  Mod Rheumatol       Date:  2014-11-17       Impact factor: 3.023

7.  Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis.

Authors:  Hiroyuki Yamashita; Kazuo Kubota; Yuko Takahashi; Ryogo Minaminoto; Miyako Morooka; Kimiteru Ito; Toshikazu Kano; Hiroshi Kaneko; Hiroshi Takashima; Akio Mimoiri
Journal:  Mod Rheumatol       Date:  2011-12-29       Impact factor: 3.023

Review 8.  Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

Authors:  Hiroyuki Yamashita; Kazuo Kubota; Akio Mimori
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

9.  Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids.

Authors:  Sarah Louise Mackie; Colin Thomas Pease; Eiji Fukuba; Emma Harris; Paul Emery; Richard Hodgson; Jane Freeston; Dennis McGonagle
Journal:  Ann Rheum Dis       Date:  2015-09-16       Impact factor: 19.103

10.  Differentiation between Polymyalgia Rheumatica (PMR) and Elderly-Onset Rheumatoid Arthritis Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Is Enthesitis a New Pathological Lesion in PMR?

Authors:  Daisuke Wakura; Takuya Kotani; Tohru Takeuchi; Tsuyoshi Komori; Shuzo Yoshida; Shigeki Makino; Toshiaki Hanafusa
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240
View more
  11 in total

Review 1.  Aortitis - An Interdisciplinary Challenge.

Authors:  Tetyana Shchetynska-Marinova; Klaus Amendt; Maliha Sadick; Michael Keese; Martin Sigl
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  An update on the unparalleled impact of FDG-PET imaging on the day-to-day practice of medicine with emphasis on management of infectious/inflammatory disorders.

Authors:  Abass Alavi; Søren Hess; Thomas J Werner; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

Review 3.  2-deoxy-2[18F]fluoro-D-glucose positron emission tomography-computed tomography in rheumatological diseases.

Authors:  Manil Subesinghe; Shaheel Bhuva; Nikita Arumalla; Andrew Cope; David D'Cruz; Sujith Subesinghe
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

Review 4.  Current Applications for Nuclear Medicine Imaging in Pulmonary Disease.

Authors:  Joanna E Kusmirek; Josiah D Magnusson; Scott B Perlman
Journal:  Curr Pulmonol Rep       Date:  2020-07-22

5.  The Utility of 18F-FDG PET/CT in Patients With Clinical Suspicion of Polymyalgia Rheumatica and Giant Cell Arteritis: A Prospective, Observational, and Cross-sectional Study.

Authors:  Amir Emamifar; Torkell Ellingsen; Søren Hess; Oke Gerke; Rasmus Hviid Larsen; Ziba Ahangarani Farahani; Per Syrak Hansen; Inger Marie Jensen Hansen; Henrik Petersen; Niels Marcussen; Michael Dahlstrøm; Pia Toftegaard; Peter Thye-Rønn
Journal:  ACR Open Rheumatol       Date:  2020-07-22

Review 6.  The Immunopathology of Giant Cell Arteritis Across Disease Spectra.

Authors:  Michelle L Robinette; Deepak A Rao; Paul A Monach
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

7.  Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  Amir Emamifar; Torkell Ellingsen; Anne Pernille Hermann; Søren Hess; Oke Gerke; Ziba Ahangarani Farahani; Per Syrak Hansen; Inger Marie Jensen Hansen; Peter Thye-Rønn
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

8.  Vasculitis and bursitis on [18F]FDG-PET/CT following COVID-19 mRNA vaccine: post hoc ergo propter hoc?

Authors:  Jan-Henning Schierz; Christine Merkel; Thomas Kittner; Farzana Ali
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-09-08       Impact factor: 9.236

9.  Clinical presentation and treatment response in patients with polymyalgia rheumatica and giant cell arteritis during a 40-week follow-up.

Authors:  Amir Emamifar; Søren Hess; Torkell Ellingsen; Oke Gerke; Ziba Ahangarani Farahani; Per Syrak Hansen; Inger Marie Jensen Hansen; Peter Thye-Rønn
Journal:  Rheumatol Adv Pract       Date:  2021-11-24

10.  Concomitant Polymyalgia Rheumatica and Large-Vessel Vasculitis Visualized on 18F-FDG PET/CT.

Authors:  Jane Maestri Brittain; Lars Christian Gormsen; Eric von Benzon; Kim Francis Andersen
Journal:  Diagnostics (Basel)       Date:  2018-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.